<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Enalapril: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Enalapril: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Enalapril: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12414" href="/d/html/12414.html" rel="external">see "Enalapril: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="83360" href="/d/html/83360.html" rel="external">see "Enalapril: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708730"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">When pregnancy is detected, discontinue enalapril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F164751"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Epaned;</li>
<li>Vasotec</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866718"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Enalapril;</li>
<li>APO-Enalapril;</li>
<li>JAMP Enalapril;</li>
<li>MAR-Enalapril;</li>
<li>NOVO-Enalapril;</li>
<li>PRO-Enalapril-10;</li>
<li>PRO-Enalapril-2.5;</li>
<li>PRO-Enalapril-20;</li>
<li>PRO-Enalapril-5;</li>
<li>RIVA-Enalapril [DSC];</li>
<li>SANDOZ Enalapril;</li>
<li>TARO-Enalapril;</li>
<li>Vasotec</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F164804"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Angiotensin-Converting Enzyme (ACE) Inhibitor;</li>
<li>
                        Antihypertensive</li></ul></div>
<div class="block doa drugH1Div" id="F164756"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Non-ST elevation acute coronary syndrome (off-label use): Note:</b> Patients should be hemodynamically stable before initiation. Use as a component of an appropriate medical regimen, which may also include antiplatelet agent(s), a beta-blocker, and a statin. Continue angiotensin-converting enzyme inhibitor therapy indefinitely for patients with concurrent diabetes, left ventricular ejection fraction ≤40%, hypertension, or stable chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718'])">Ref</a></span>). Dosing is based on expert opinion and general dosing range in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 2.5 to 5 mg in 1 or 2 divided doses (depending on initial blood pressure); titrate slowly based on tolerability and response up to 40 mg/day in 1 or 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Reeder.1','lexi-content-ref-Reeder.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Reeder.1','lexi-content-ref-Reeder.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ST-elevation myocardial infarction (off-label use):</b>
<b>Note: </b>Patients should be hemodynamically stable before initiation. Use as a component of an appropriate medical regimen, which may also include antiplatelet agent(s), a beta-blocker, and a statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>). Dosing is based on expert opinion and general dosing range in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 2.5 to 5 mg in 1 or 2 divided doses (depending on initial blood pressure); titrate slowly based on tolerability and response up to 40 mg/day in 1 or 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Reeder.1','lexi-content-ref-Reeder.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Reeder.1','lexi-content-ref-Reeder.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>If tolerated<b>, </b>an angiotensin II receptor-neprilysin inhibitor is generally preferred over an angiotensin-converting enzyme inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 mg twice daily; increase dose (eg, double) as tolerated every ≥1 to 2 weeks to a target dose of 10 to 20 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>). In hospitalized patients, may titrate more rapidly as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyer.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Note:</b> For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use with another appropriate agent (eg, long-acting dihydropyridine calcium channel blocker or thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose (eg, increase the daily dose by doubling), as needed, up to 40 mg/day in 1 or 2 divided doses; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.2019a'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb3e0e84-695b-4274-ae22-e40f72895c16">Posttransplant erythrocytosis, kidney transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttransplant erythrocytosis, kidney transplant recipients (off-label use): Note: </b>For patients with a hemoglobin concentration &gt;17 g/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vlahakos.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vlahakos.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 or 5 mg daily; if inadequate response seen within 4 weeks, may titrate up to 40 mg/day based on hemoglobin and blood pressure response; if hemoglobin remains &gt;17 g/dL after an additional 4 weeks, consider additional therapy (eg, phlebotomy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8938674','lexi-content-ref-7778179','lexi-content-ref-7645558','lexi-content-ref-8165703','lexi-content-ref-Vlahakos.1','lexi-content-ref-11502994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8938674','lexi-content-ref-7778179','lexi-content-ref-7645558','lexi-content-ref-8165703','lexi-content-ref-Vlahakos.1','lexi-content-ref-11502994'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d8b6822-d348-4d03-bd66-4ea05b5dd0a9">Proteinuric chronic kidney disease, diabetic or nondiabetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuric chronic kidney disease, diabetic or nondiabetic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 5 mg in 1 or 2 divided doses depending on baseline BP; titrate gradually (eg, by doubling the dose every 2 to 4 weeks) up to the maximally tolerated dose, not to exceed 40 mg/day in 1 or 2 divided doses. If proteinuria target is not met despite optimized dosage, consider additional therapies (eg, sodium-glucose cotransporter-2 inhibitor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-Perkovic.1','lexi-content-ref-12761258','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-Perkovic.1','lexi-content-ref-12761258','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">Conversion from IV <b>enalaprilat</b> to oral <b>enalapril</b> therapy: If not concurrently receiving diuretics, initiate enalapril 5 mg once daily; if concurrently receiving diuretics and responding to enalaprilat 0.625 mg IV every 6 hours, initiate with enalapril 2.5 mg once daily; subsequent titration as needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990434"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>(expert opinion derived from Elung-Jensen 2003; Hoyer 1993; Kelly 1986; MacFadyen 1993; Sica 1991; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 30 mL/minute: Initial: 2.5 mg daily in 1 or 2 divided doses; titrate slowly based on tolerability and response. Maximum recommended dose: 20 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Consider alternative therapy; risk of adverse effects or complications (eg, hyperkalemia, kidney failure) are increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Initial: 1.25 mg once daily (or 2.5 mg every other day); titrate slowly based on tolerability and response. Maximum recommended dose: 10 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~45% [enalaprilat]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2853960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2853960'])">Ref</a></span>): <b>Note:</b> Avoid use if an AN69 hemofilter is used (associated with anaphylactoid reaction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879671'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 2.5 mg 3 times weekly administered post dialysis on dialysis days; titrate slowly based on tolerability and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Maximum recommended dose: 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzable (manufacturer’s labeling): Dose as in CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Dose as in CrCl 10 to 30 mL/minute (expert opinion). Avoid use if an AN69 hemofilter is used (associated with anaphylactoid reaction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879671'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Dose as in CrCl 10 to 30 mL/minute (expert opinion). Avoid use if an AN69 hemofilter is used (associated with anaphylactoid reaction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879671'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Conversion from IV <b>enalaprilat</b> to oral <b>enalapril</b> therapy:</i></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 mL/minute: May initiate enalapril 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 30 mL/minute: May initiate enalapril 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: May initiate enalapril 1.25 mg once daily.</p></div>
<div class="block doha drugH1Div" id="F50987617"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. Hydrolysis of enalapril to enalaprilat may be delayed and/or impaired in patients with severe hepatic impairment, but the pharmacodynamic effects of the drug do not appear to be significantly altered. Use with caution, particularly in patients with ascites due to cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-23463403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-23463403'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F164757"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F164779"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="83360" href="/d/html/83360.html" rel="external">see "Enalapril: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86fd017b-f098-427e-b843-c16a24638f11">Heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure:</b> Limited data available: Infants, Children and Adolescents: Oral: Initial: 0.1 mg/kg/day in 1 to 2 divided doses; increase as tolerated and based on clinical response over 2 weeks to maximum daily dose of 0.5 mg/kg/<b>day</b>; one pediatric study (n=63, age range: 9 days to 17.2 years, dosage range: 0.04 to 0.94 mg/kg/day) reported improvement in 39 patients at a mean dose of 0.36 ± 0.24 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8110005','lexi-content-ref-16494512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8110005','lexi-content-ref-16494512'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Infants, Children and Adolescents: Oral: Initial: 0.08 mg/kg/day in divided doses once or twice daily, maximum initial daily dose: 5 mg/<b>day</b>; adjust dose based on blood pressure response; maximum daily dose: 0.6 mg/kg/<b>day</b> not to exceed 40 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="445dcc27-ce8e-4b09-87b1-740ec35ee022">Proteinuria, nephrotic syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuria, nephrotic syndrome:</b> Limited data available: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing: Children ≥7 years and Adolescents: 2.5 to 5 mg/day was reported in a retrospective study in normotensive pediatric patients as either monotherapy (n=17; mean age: 13.7 years; range: 8 to 17 years) or with prednisone (n=11; mean age: 12.6 years; range: 7 to 16 years); significant decrease in proteinuria (with or without nephrotic syndrome) occurred; no significant change in blood pressure was observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10645036']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10645036'])">Ref</a></span>); a case series of three adolescents with sickle anemia nephropathy reported an initial dose of 5 mg/day; one patient required an increase to 7.5 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15704213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15704213'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing: Children and Adolescents: Initial: 0.2 mg/kg/day; titrate to response at 4- to 12-week intervals; range: 0.2 to 0.6 mg/kg/day; maximum daily dose: 20 mg/<b>day</b>; a crossover dose comparison trial showed effects on proteinuria were dose-dependent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14648339','lexi-content-ref-17299000','lexi-content-ref-11045392','lexi-content-ref-10879662','lexi-content-ref-12920631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14648339','lexi-content-ref-17299000','lexi-content-ref-11045392','lexi-content-ref-10879662','lexi-content-ref-12920631'])">Ref</a></span>); if combined with other angiotensin blockade (ARB), lower doses have been reported (0.1 to 0.16 mg/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17299000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17299000'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108467"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Use in infants, children, and adolescents ≤16 years of age with GFR &lt;30 mL/minute/1.73 m<sup>2</sup> is not recommended; dosing data not available in this population.</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis: Administer 50% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: Administer 50% of usual dose.</p></div>
<div class="block dohp drugH1Div" id="F51128320"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Hydrolysis of enalapril to enalaprilat may be delayed and/or impaired in patients with severe hepatic impairment, but the pharmacodynamic effects of the drug do not appear to be significantly altered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32835726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32835726'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F56291764"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use may be associated with <b>increased blood urea nitrogen</b> and <b>increased serum creatinine</b>, resulting in <b>oliguria</b> and <b>acute kidney injury</b> (AKI) in all ages. Increases in serum creatinine are expected and usually stabilize within 20% to 30% of baseline; higher increases may indicate high efferent tone (such as with hypovolemia, congestive heart failure, or renal artery stenosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9861226','lexi-content-ref-1315003','lexi-content-ref-KDIGO.2012','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9861226','lexi-content-ref-1315003','lexi-content-ref-KDIGO.2012','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to pharmacologic action; inhibits efferent arteriolar vasoconstriction, lowering glomerular filtration pressure (and inhibiting renal autoregulation), which can lead to a reduction in the glomerular filtration rate (GFR). Kidney hypoperfusion from systemic hypotension may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8773167','lexi-content-ref-10724055','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8773167','lexi-content-ref-10724055','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; increases in serum creatinine generally occur within 2 weeks of initiation and stabilize within 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10724055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10724055'])">Ref</a></span>). However, more immediate increases may occur in patients with other risk factors for AKI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22754420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22754420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with low renal blood flow whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II, including (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">- Low effective circulating volume (sodium or volume depletion)</p>
<p style="text-indent:-2em;margin-left:8em;">- Congestive heart failure</p>
<p style="text-indent:-2em;margin-left:8em;">- Hypotension or shock</p>
<p style="text-indent:-2em;margin-left:8em;">- Renal artery stenosis</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose at initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age:</p>
<p style="text-indent:-2em;margin-left:8em;">- Neonates; risk may be higher in preterm neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24233240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24233240'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent diuretic and/or nonsteroidal anti-inflammatory drug use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27490717','lexi-content-ref-31888533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27490717','lexi-content-ref-31888533'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Angioedema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema</b> may occur rarely; edema may manifest in the head and neck (potentially compromising the airway) or the intestine (presenting as abdominal pain). Use is contraindicated in patients with idiopathic or hereditary angioedema or previous angioedema associated with any angiotensin-converting enzyme inhibitors or neprilysin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-28994183','lexi-content-ref-31445588','lexi-content-ref-29884969','lexi-content-ref-25176015','lexi-content-ref-25578409','lexi-content-ref-33492725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-28994183','lexi-content-ref-31445588','lexi-content-ref-29884969','lexi-content-ref-25176015','lexi-content-ref-25578409','lexi-content-ref-33492725'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action (ie, increased bradykinin and substance P, vascular permeability, vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25058867','lexi-content-ref-29884969','lexi-content-ref-32766265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25058867','lexi-content-ref-29884969','lexi-content-ref-32766265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur at any time during treatment. Most cases occur within the first week of therapy but may also occur years after therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-2840522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-2840522'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Black patients (estimated 4- to 5-fold higher risk); the mechanism for this is not completely understood but may be related to genetic variants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-8689816','lexi-content-ref-28994183','lexi-content-ref-16043683','lexi-content-ref-29884969','lexi-content-ref-32496628','lexi-content-ref-18413488','lexi-content-ref-31835086','lexi-content-ref-20625347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-8689816','lexi-content-ref-28994183','lexi-content-ref-16043683','lexi-content-ref-29884969','lexi-content-ref-32496628','lexi-content-ref-18413488','lexi-content-ref-31835086','lexi-content-ref-20625347'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29884969','lexi-content-ref-18413488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29884969','lexi-content-ref-18413488'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking history (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29884969','lexi-content-ref-15482412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29884969','lexi-content-ref-15482412'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous history of angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-9218671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-9218671'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25058867','lexi-content-ref-16043683','lexi-content-ref-29884969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25058867','lexi-content-ref-16043683','lexi-content-ref-29884969'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Seasonal allergies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16043683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16043683'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of mechanistic target of rapamycin (mTOR) inhibitors (eg, everolimus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28994183','lexi-content-ref-20093343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28994183','lexi-content-ref-20093343'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of neprilysin inhibitor (contraindicated)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cough</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A dry, hacking, nonproductive <b>cough </b>that is typically associated with tickling or scratching in the throat may occur with angiotensin converting enzyme inhibitors (ACEI) in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20130570','lexi-content-ref-21035591','lexi-content-ref-16428706','lexi-content-ref-23869492','lexi-content-ref-1616218','lexi-content-ref-26871774','lexi-content-ref-10644922','lexi-content-ref-8703645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20130570','lexi-content-ref-21035591','lexi-content-ref-16428706','lexi-content-ref-23869492','lexi-content-ref-1616218','lexi-content-ref-26871774','lexi-content-ref-10644922','lexi-content-ref-8703645'])">Ref</a></span>). Recurrence is likely with rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8862965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8862965'])">Ref</a></span>). Resolution of cough typically occurs 1 to 4 weeks after ACEI discontinuation but may persist for up to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Various proposed mechanisms. May be related to pharmacologic action (ie, increased bradykinin and substance P, resulting in accumulation in the lungs and bronchoconstriction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428706','lexi-content-ref-1616218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428706','lexi-content-ref-1616218'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; within hours to 4 weeks after initiation but can be delayed for up to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767167','lexi-content-ref-7848615','lexi-content-ref-25992489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767167','lexi-content-ref-7848615','lexi-content-ref-25992489'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Possibly certain genetic variants (some of which may be independent of the bradykinin pathway) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28084903','lexi-content-ref-24743543','lexi-content-ref-26607661','lexi-content-ref-32397904','lexi-content-ref-30672376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28084903','lexi-content-ref-24743543','lexi-content-ref-26607661','lexi-content-ref-32397904','lexi-content-ref-30672376'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia </b>(elevated serum potassium) may occur with angiotensin-converting enzyme inhibitors (ACEI), including enalapril (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9861226','lexi-content-ref-15295051','lexi-content-ref-20150448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9861226','lexi-content-ref-15295051','lexi-content-ref-20150448'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action; inhibits formation of circulating angiotensin II, which leads to efferent arteriole vasodilation and subsequent lowering of glomerular filtration rate, which lowers potassium elimination. Additionally, ACEI interfere with the generation and release of aldosterone from the adrenal cortex, leading to an impairment of potassium excretion from the kidney (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31119681','lexi-content-ref-15295051','lexi-content-ref-20150448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31119681','lexi-content-ref-15295051','lexi-content-ref-20150448'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Disease states associated with hyperkalemia (congestive heart failure, diabetes mellitus, chronic kidney disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31226134','lexi-content-ref-31119681','lexi-content-ref-20150448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31226134','lexi-content-ref-31119681','lexi-content-ref-20150448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications which cause hyperkalemia (ACEI, angiotensin receptor blockers, spironolactone, nonsteroidal anti-inflammatory drugs, beta blockers, heparin, tacrolimus, cyclosporine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31226134','lexi-content-ref-32291375','lexi-content-ref-15295051','lexi-content-ref-21883995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31226134','lexi-content-ref-32291375','lexi-content-ref-15295051','lexi-content-ref-21883995'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute kidney injury (elevated BUN and/or serum creatinine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051','lexi-content-ref-9437375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051','lexi-content-ref-9437375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dietary intake of potassium or concomitant use of potassium supplements (including potassium-containing salt substitutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32291375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32291375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline elevated potassium level (≥5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051','lexi-content-ref-9437375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051','lexi-content-ref-9437375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;70 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10619572'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F164711"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency ranges include data from hypertension and heart failure trials. Higher rates of adverse reactions have generally been noted in patients with heart failure. However, the frequency of adverse effects associated with placebo is also increased in this population.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≤7%), orthostatic hypotension (2%), syncope (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (2%), nausea (1%), vomiting (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (8%), headache (2%), orthostatic dizziness (1% to 2%), vertigo (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (1%), cough (1% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Cough table link" class="lexi-table-link" data-table-id="lexi-content-cough" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cough')">table 1</a>)</span><span class="table-link" style="display:none;">Cough</span>, dyspnea (1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cough" frame="border" id="lexi-content-cough" rules="all">
<caption style="text-align:center;">
<b>Enalapril: Adverse Reaction: Cough</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Enalapril)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Enalapril)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiac failure</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">673</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">339</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,314</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">230</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation, atrial tachycardia, bradycardia, cardiac arrhythmia, cerebrovascular accident, flushing, palpitations, pulmonary embolism, Raynaud's disease</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, diaphoresis, erythema multiforme, exfoliative dermatitis, pemphigus, pruritus, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, constipation, dysgeusia, dyspepsia, glossitis, intestinal obstruction, melena, sore throat, stomatitis, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence, oliguria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression, neutropenia <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, anosmia, ataxia, confusion, depression, drowsiness, dysesthesia, flank pain, insomnia, nervousness, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, conjunctivitis, dry eye syndrome, lacrimation</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, bronchospasm, eosinophilic pneumonitis, hoarseness, pulmonary edema, pulmonary infarct, pulmonary infiltrates, rhinorrhea, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Psoriasis (Song 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia (Llop 1994), hyperkalemia (Albareda 1998), hyponatremia (Gonzalez-Martinez 1993)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (Carnovale 2003, Maringhini 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Agranulocytosis (Elis 1991), decreased hematocrit (Graafland 1992, Ozbek 1997), decreased hemoglobin (Graafland 1992, Ozbek 1997), eosinophilia (Barnes 1983), hemolysis (with G6PD), hemolytic anemia, increased erythrocyte sedimentation rate, leukocytosis, positive ANA titer, thrombocytopenia (Ackroyd 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice (Todd 1990), hepatic failure (Jeserich 2000), hepatitis (Macias 2003), increased liver enzymes (Macias 2003), increased serum bilirubin (Macias 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Sato 2021), nonimmune anaphylaxis (Tunon-de-Lara 1992)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral neuropathy (Hormigo 1992), visual hallucination (Doane 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (Peppers 1995), arthritis, myalgia (Peppers 1995), myositis, serositis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Hennesy 1992), renal insufficiency (Albareda 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F164728"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to enalapril or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; idiopathic or hereditary angioedema; concomitant use with aliskiren in patients with diabetes mellitus; coadministration with or within 36 hours of switching to or from a neprilysin inhibitor (eg, sacubitril).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with aliskiren-containing drugs in patients with moderate to severe kidney impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>).</p></div>
<div class="block war drugH1Div" id="F164708"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Anaphylactic reactions/nonimmune anaphylaxis can occur with ACE inhibitors. Severe nonimmune anaphylaxis may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of nonimmune anaphylaxis have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/Syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses). Effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation. Close monitoring of patient is required, especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use, especially in patients with HF where a reduction in systolic blood pressure is a desirable observation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ascites: Generally, avoid use in patients with ascites due to cirrhosis or refractory ascites; if use cannot be avoided in patients with ascites due to cirrhosis, monitor BP and kidney function carefully to avoid rapid development of kidney failure (AASLD [Runyon 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs. In a retrospective cohort study of elderly patients (≥65 years of age) with myocardial infarction and impaired left ventricular function, administration of an ACE inhibitor was associated with a survival benefit, including patients with serum creatinine concentrations &gt;3 mg/dL (265 micromol/L) (Frances 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">• Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant kidney impairment; may be at increased risk for hematologic toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Use with caution in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (AHA/ACC [Ommen 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in preexisting kidney insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Race/Ethnicity: In Black patients, the BP-lowering effects of ACE inhibitors may be less pronounced. The exact mechanism is not known; differences in the renin-angiotensin-aldosterone system, low renin levels, and salt sensitivity more commonly found in Black patients may contribute (Brewster 2013; Helmer 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: In patients on chronic ACE inhibitor therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension. However, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis 2011). Based on current research and clinical guidelines in patients undergoing non-cardiac surgery, continuing ACE inhibitors is reasonable in the perioperative period. If ACE inhibitors are held before surgery, it is reasonable to restart postoperatively as soon as clinically feasible (ACC/AHA [Fleisher 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Oral solution: May contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol. Large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982). Some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F164720"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as maleate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epaned: 1 mg/mL (150 mL) [contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (150 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as maleate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vasotec: 2.5 mg, 5 mg, 10 mg, 20 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F164704"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F164730"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Enalapril Maleate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $4.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Epaned Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $4.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Enalapril Maleate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.52 - $1.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.67 - $1.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.26 - $1.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $1.00 - $2.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Vasotec Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $21.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $24.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $26.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $38.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866719"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as maleate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vasotec: 5 mg, 10 mg, 20 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg, 20 mg</p></div>
<div class="block adm drugH1Div" id="F49095530"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals.</p></div>
<div class="block admp drugH1Div" id="F52612681"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer without regard to food.</p></div>
<div class="block use drugH1Div" id="F164723"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction:</b> Treatment of symptomatic heart failure with reduced ejection fraction (HFrEF) to improve symptoms, increase survival, and decrease hospitalizations. In patients with stable asymptomatic HFrEF, enalapril decreases the risk of developing overt heart failure and the incidence of heart failure hospitalizations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b> Management of hypertension, alone or in combination with other antihypertensive agents.</p></div>
<div class="block off-label drugH1Div" id="F25725544"><span class="drugH1">Use: Off-Label: Adult</span><p>Non-ST-elevation acute coronary syndrome; Posttransplant erythrocytosis, kidney transplant recipients; Proteinuric chronic kidney disease, diabetic or nondiabetic; Stable coronary artery disease; ST-elevation myocardial infarction</p></div>
<div class="block mst drugH1Div" id="F164813"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Enalapril may be confused with Anafranil, Elavil, Eldepryl, ramipril</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Acepril [Hungary, Switzerland] may be confused with Accupril which is a brand name for quinapril [US, Canada, multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Acepril: Brand name for enalapril [Hungary, Switzerland], but also brand name for captopril [Great Britain]; lisinopril [Malaysia]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F164797"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F164713"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: Angiotensin-Converting Enzyme Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alteplase: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Alteplase. Specifically, the risk for angioedema may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II: Angiotensin-Converting Enzyme Inhibitors may enhance the therapeutic effect of Angiotensin II. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives when possible. Monitor blood pressure, renal function, and potassium if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprotinin: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: Angiotensin-Converting Enzyme Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Gluconate: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Hydroxide Polymaltose Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gelatin (Succinylated): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gelatin (Succinylated). Specifically, the risk of a paradoxical hypotensive reaction may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icatibant: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Dextran Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Administer angiotensin-converting enzyme (ACE) inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Angiotensin-Converting Enzyme Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor for increased concentrations/toxic effects of lithium if an ACE inhibitor is initiated/dose increased, or if switching between ACE inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pregabalin: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Racecadotril: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk for angioedema may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacubitril: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Sacubitril. Specifically, the risk of angioedema may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus Products: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk for angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenapanor: May decrease serum concentrations of the active metabolite(s) of Enalapril. Tenapanor may decrease the serum concentration of Enalapril.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: May interact via an unknown mechanism with Angiotensin-Converting Enzyme Inhibitors. Management: Avoid concomitant use of urapidil and angiotensin-converting enzyme (ACE) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49160666"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Avoid use of angiotensin-converting enzyme (ACE) inhibitor therapy in patients who may become pregnant and who are not using effective contraception (ADA 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Angiotensin-converting enzyme (ACE) inhibitors are fetotoxic. Transition patients prior to conception to an agent preferred for use during pregnancy unless treatment with an ACE inhibitor is absolutely necessary (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019). Closely monitor pregnant patients on ACE inhibitors with serial ultrasounds.</p>
<p style="text-indent:0em;margin-top:2em;">When ACE inhibitors are used for the treatment of proteinuric chronic kidney disease in patients who could become pregnant, discontinue use at the first positive pregnancy test (ADA 2021; Fakhouri 2022).</p>
<p style="text-indent:0em;margin-top:2em;">ACE inhibitors are not recommended for the treatment of heart failure in patients planning to become pregnant (AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block pri drugH1Div" id="F164731"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Enalapril crosses the placenta; the active metabolite enalaprilat can be detected in the newborn (Schubiger 1988).</p>
<p style="text-indent:0em;margin-top:2em;">Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Exposure to an angiotensin-converting enzyme (ACE) inhibitor during the first trimester of pregnancy may be associated with an increased risk of fetal malformations (ACOG 2019; ESC [Regitz-Zagrosek 2018]). Following exposure during the second or third trimesters, drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Oligohydramnios may not appear until after an irreversible fetal injury has occurred. ACE inhibitor use during pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Monitor infants exposed to an ACE inhibitor in utero for hyperkalemia, hypotension, and oliguria. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Discontinue ACE inhibitors as soon as possible once pregnancy is detected. Agents other than ACE inhibitors are recommended for the treatment of chronic hypertension during pregnancy (ACOG 2019; ESC [Cífková 2020]; SOGC [Magee 2022]). Consider the use of ACE inhibitors only for pregnant patients with hypertension refractory to other medications (ACOG 2019). Closely monitor pregnant patients on ACE inhibitors with serial ultrasounds.</p>
<p style="text-indent:0em;margin-top:2em;">ACE inhibitors are not recommended for the treatment of heart failure or proteinuric chronic kidney disease during pregnancy (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]; Fakhouri 2022).</p></div>
<div class="block brc drugH1Div" id="F6197985"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Enalapril and enalaprilat are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of enalapril and enalaprilat in breast milk are available from multiple reports.</p>
<p style="text-indent:-2em;margin-left:4em;">• Enalapril and enalaprilat breast milk concentrations were evaluated in one patient who was 12 months' postpartum following administration of enalapril 10 mg/day for 11 months. The highest level of enalapril was 2.05 ng/mL at 4 hours after the dose. The highest level of enalaprilat was 0.75 ng/mL at 8.75 hours after the dose (Rush 1991).</p>
<p style="text-indent:-2em;margin-left:4em;">• The presence of enalaprilat in breast milk was evaluated in three patients, one treated with enalapril 5 mg for chronic glomerulonephritis and two treated with enalapril 10 mg for hypertension. Enalaprilat was not detected in breast milk (&lt;0.2 ng/mL) of any patient 4 hours after the maternal dose. Serum concentrations of enalaprilat were significantly greater (179 ng/mL) in the first woman, who also had renal impairment, when compared to the two patients treated for hypertension (48 ng/mL, 23.9 ng/mL). Enalapril concentrations were not evaluated (Huttunen 1989).</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk concentrations of enalapril and enalaprilat were evaluated in five lactating patients treated for hypertension. Following a single dose of enalapril 20 mg, breast milk was sampled over 24 hours; serum samples were obtained at 2 and 4 hours. Breast milk concentrations of enalapril ranged from 0 to 5.9 mcg/mL with the highest concentration observed 6 hours after the dose (maximum maternal serum concentrations: 92 to 151 ng/mL). Enalapril was not detectable in the breast milk of one patient over the 24-hour dosing interval (maternal serum concentration: 151 ng/mL). Concentrations of enalaprilat ranged from 0 to 2.3 ng/mL (maximum maternal serum concentrations: 39 to 112 ng/mL). Peak breast milk concentrations of the metabolite occurred 6 hours after the dose in one patient and at 24 hours in two others; the metabolite was only measurable in a third patient at 24 hours. Mean peak breast milk concentrations for enalapril and enalaprilat were 1.74 ng/mL and 1.72 ng/mL, respectively (Redman 1990). Using the highest breast milk concentration of 5.9 ng/mL, the estimated exposure of enalapril to the breastfeeding infant would be 0.00089 mg/kg/day (relative infant dose: 1.1% based on a therapeutic infant dose of 0.08 mg/kg/day).</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer. When postpartum treatment with an ACE inhibitor is needed, available guidelines consider enalapril to be acceptable for use (AHA/ACC/HFSA [Heidenreich 2022], ESC [Cífková 2020]). Avoid breastfeeding if high maternal doses of an ACE inhibitor are needed (ACOG 2019).</p></div>
<div class="block dic drugH1Div" id="F164733"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Limit salt substitutes or potassium-rich diet.</p></div>
<div class="block mop drugH1Div" id="F164718"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP; BUN; serum creatinine; electrolytes (eg, potassium [especially in patients on concomitant potassium-sparing diuretics, potassium supplements and/or potassium containing salts]); if patient has collagen vascular disease and/or kidney impairment, periodically monitor CBC with differential. If angioedema is suspected, assess risk of airway obstruction (eg, involvement of tongue, glottis, larynx, and/or history of airway surgery).</p></div>
<div class="block pha drugH1Div" id="F164707"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion</p></div>
<div class="block phk drugH1Div" id="F164727"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: ~1 hour</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 4 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 12 to 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: 55% to 75%</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~50% (Davies 1984)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Prodrug, undergoes hepatic biotransformation to enalaprilat</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Enalapril: CHF: Neonates (n=3, PNA: 10 to 19 days): 10.3 hours (range: 4.2 to 13.4 hours) (Nakamura 1994); CHF: Infants and Children ≤6.5 years of age (n=11): 2.7 hours (range: 1.3 to 6.3 hours) (Nakamura 1994); Adults: Healthy: 2 hours; CHF: 3.4 to 5.8 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Enalaprilat: CHF: Neonates (n=3, PNA: 10 to 19 days): 11.9 hours (range: 5.9 to 15.6 hours) (Nakamura 1994); CHF: Infants and Children ≤6.5 years of age (n=11): 11.1 hours (range: 5.1 to 20.8 hours) (Nakamura 1994); Infants 6 weeks to 8 months of age: 6 to 10 hours (Lloyd 1989); Adults: ~35 hours (Till 1984; Ulm 1982)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: Enalapril: 0.5 to 1.5 hours; Enalaprilat (active metabolite): 3 to 4.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (61%; 18% of which was enalapril, 43% was enalaprilat); feces (33%; 6% of which was enalapril, 27% was enalaprilat) (Ulm 1982)</p></div>
<div class="block phksp drugH1Div" id="F51154038"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In those with glomerular filtration rate (GFR) 30 mL/minute or less, the peak and trough enalaprilat levels increase, T<sub>max</sub> increases, and time to steady state may be delayed.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F164734"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Angiotec | Enapress | Enapril | Envas | Invoril | Narapril | Renitec | Vasopril</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Arteriopril | Baypril | Bonuten | Defluin | Dentromin | Ecaprilat | Eitan | Enalafel | Enalapril gen med | Enalapril Puntanos | Enalapril richet | Enalapril vent 3 | Enatral | Enatrial | Endopril | Eritril | Fabotensil | Fada enalapril | Gadopril | Hipertan | Kinfil | Laprilena | Lotrial | Nalapril | Natam | Presipril | Presiregul | Priltenk | Renitec | Sulocten | Tencas | Unicard | Vapresan | Vasopril</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Alapril | Enac | Enalapril 1a pharma gmbh | Enalapril genericon pharma | Enalapril ranbaxy | Enalapril Ratiopharm | Enalapril sandoz | Enalaprilmaleat Alternova | Enalaprilmaleate arcana | Enapril | Mepril | Renistad | Renitec</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Acetec | Alphapril | Amprace | Apo enalapril | Auspril | Cm enalapril | Enahexal | Enalabell | Enalapril Actavis | Enalapril an | Enalapril bc | Enalapril GA | Enalapril Generic Health | Enalapril pfizer | Enalapril sandoz | Enalapril Winthrop | Enalapril-dp | Genrx Enalapril | Malean | Renitec | Renitec m | Tw enalapril</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acepril | Anapril | Ednyt | Enaril | Eril | Minipril | Vasopril</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docenala | Enalapril bc | Enalapril eurogenerics | Enalapril merck-generics | Enalapril Ratiopharm | Enalapril sandoz | Enalapril teva generics belgium | Renitec</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Ena denk | Fairpril | Renitec</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Berlipril | Enahexal | Enalapril | Enap | Enapril | Enpril | Invoril | Laprilen | Renapril | Renitec | Vasopren</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Angiopril | Atens | Cardionato | Enalabal | Enalamed | Enalap | Enalapril | Enalatec | Enalil | Enalprin | Enaplex | Enapril | Enaprotec | Enatec | Enatil | Eupressin | Flossotec | Glioten | Lapritec | Maleapril | Maleato de enalapril | Maleato de enalapril biolab gen | Multipressin | Neolapril | Pressel | Pressocord | Pressomede | Pressotec | Pryltec | Renalapril | Renapril | Renipress | Renitec | Renopril | Sanvapress | Sifpryl | Vasopril</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Acepril | Enalapril 1 A Pharma | Enalapril Actavis | Enalapril Adico | Enalapril helvepharm | Enalapril sandoz | Enalapril Spirig | Enalapril spirig hc | Enalapril teva | Enalapril zentiva | Enalapril-servipharm | Enalapril-trendpharm | Enatec | Epril | Reniten | Reniten mite | Reniten mite rpd | Reniten rpd | Reniten submite | Reniten submite rpd</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Cardace</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bajaten | Enalapril | Enalten | Esalfon | Glioten | Grifopril | Hiperson | Hipoartel | Lotrial | Prevol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Apo enalapril | Benalapril | Enalapril | Invoril | Ling guang li | Qin ke xi | Qing ke xi | Renitec | Yi na lin | Yi su | Yin fu er</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Biocronil | Biolapril | Donapril | Enacar | Enaladil | Enalapril | Enalapril maleato | Enalapril MK | Enalasyn | Enaprex | Enetil | Glioten | Lotrial | Novopril | Presun | Presuren | Renitec | Tesoren | Unipril</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Acetensil | Apo enalapril | Berlipril | E cor | Ednyt | Enalapril | Enalapril al | Enalapril Lachema | Enalapril Ratiopharm | Enalapril vitabalans | Enalek | Enap | Enapirex | Enapril | Renitec</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Benalapril | Corvo | Ena | Ena Hennig | Enabeta | Enadigal | Enadura | Enahexal | Enal | Enalagamma | Enalapril | Enalapril Accedo | Enalapril Actavis | Enalapril al | Enalapril Corax | Enalapril dura | Enalapril Heumann | Enalapril merck | Enalapril Ratiopharm | Enalapril sandoz | Enalapril stada | Enalapril Verla | Enalapril vitabalans | Enalapril von ct | Enalapril wolff | Enalapril-Ct | Enalapril-saar | Enalaprilx | Enalich | Enalind | Jutaxan | Pres | Renitec | Xanef</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Corodil | Enacodan | Enalapril biochemie | Enalapril krka | Enalapril nm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alprilen | Ardilan | Betapril | Biocronil | Cardiopres | Controlvas | Ditensil | Ecaprinil | Enalacor | Enalap | Enalapril | Enalapril maleato | Enaldun | Enalten | Enaprex | Eno Pres | Fralapril | Glioten | Hipervac | Lotrial | Naprilex | Neotensin | Nor-Prilat | Normapres | Norpril | Pinapril | Presopril | Renipress | Renitec | Sulapril | Tensal | Tensotec</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acetensil | Biopril | Cardiol | Danapril | Decliten | Ecaprinil | Ecastar | Enalapril | Enalapril magma | Enalapril maleato | Enalapril MK | Enalten | Enaplus | Enapril | Evapril | Glioten | Grifopril | Kro pril | Lotrial | Omnipress | Omnipress HCT | Prilace | Raserpril | Renitec | Vasolat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Berlipril | Ednyt | Enahexal | Enalapril | Enalapril Ratiopharm | Enalapril vitabalans | Enalapril-mepha | Enap | Enatec | Enypril ns | Invoril | Renitec</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acapril | Enalap | Ezapril | Pres | Presslight | Renitec</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acetensil | Baripril | Bitensil | Clipto | Controlvas | Corprilor | Crinoren | Dabonal | Ditensor | Enalapril | Enalapril agen | Enalapril alter | Enalapril aphar | Enalapril aristo | Enalapril aurovitas | Enalapril bayvit | Enalapril belmac | Enalapril bexal | Enalapril cinfa | Enalapril cuve | Enalapril davur | Enalapril durban | Enalapril edigen | Enalapril grapa | Enalapril juventus | Enalapril kern | Enalapril Korhispana | Enalapril lareq | Enalapril Lasa | Enalapril Mabo | Enalapril merck | Enalapril normon | Enalapril Pensa | Enalapril Pharmagenus | Enalapril Qualigen | Enalapril ranbaxy | Enalapril Ratiopharm | Enalapril Rimafar | Enalapril sandoz | Enalapril Sumol | Enalapril tamarang | Enalapril tarbis | Enalapril Tecnigen | Enalapril uxafarma | Enalapril vir | Enalapril Winthrop | Herten | Hipoartel | Iecatec | Insup | Nacor | Naprilene | Neotensin | Pressitan | Reca | Renitec</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ena denk | Korandil | Narapril</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Enalapril alternova | Enalapril generics | Enalapril ivax | Enalapril krka | Enalapril Merck NM | Enalapril orion | Enalapril pliva | Enalapril ranbaxy | Enalapril Ratiopharm | Enalapril sandoz | Enalatin | Enaloc | Enapress | Linatil | Linatilsan | Renitec</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Enalapril Actavis | Enalapril Almus | Enalapril arrow | Enalapril biogaran | Enalapril eg | Enalapril evolugen | Enalapril g gam | Enalapril gnr | Enalapril irex | Enalapril ivax | Enalapril merck | Enalapril qualimed | Enalapril ranbaxy | Enalapril Ratiopharm | Enalapril rpg | Enalapril sandoz | Enalapril teva | Enalapril Zydus | Renitec</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Enalapril | Enalapril Almus | Enalapril arrow | Enalapril cox | Enalapril kent | Enalapril sandoz | Encardil | Euril | Innovace | Pralenal | Sinalapril</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Agioten | Analept | Antiprex | Enalapril | Erxetilan | Gnostocardin | Kaparlon s | Kontic | Leovinezal | Megapress | Octorax | Ofnifenil | Protal | Rablas | Renitec | Stadelant | Supotron | Ulticadex | Virfen | Vitobel</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Bonapress</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Anapril | Apo enalapril | Enalapril | Enalapril Actavis | Enap | Enapril | Renitec | Zynace</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Enap | Enazil | Olivin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Acepril | Berlipril | Ednyt | Enahexal | Enalapril | Enalapril Ratiopharm | Enalatidin | Enap | Enapril | Invoril | Renitec</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Inoprilat | Meipril | Renacardon | Renivace | Repanitril | Tenace</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ednyt | Enap | Innomel | Innovace</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Convertin | Enaladex | Enalapril</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Anze | Bql | Canapril | Converten | Dilpril | Dilvas | E-pril | El | Ena | Enace | Enal | Enalapril | Enalcyp | Enam | Enamate | Enap | Enaped | Enapril | Enariv | Enaten | Encardil | Eneril | Enlow | Enpril | Enstal | Envapen | Envas | Eopril | Epm | Epril | Hytrol | Invoril | Lupinace | Minipril | Myoace | Myopril | Normace | Nuril | Oren | Tenam | Tenfri | Vasonorm | Viviril</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Safapril</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Daren | Renitec</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Converten | Enalapril | Enalapril Actavis | Enalapril Age | Enalapril Almus | Enalapril doc generici | Enalapril eg | Enalapril germed | Enalapril Pensa | Enalapril ranbaxy | Enalapril sigma tau | Enalapril teva | Enapren | Marek | Naprilene | Prilenor | Silverit</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ace Press | Angiotec | Lapril | Renitec | Ulticadex | Vasopril | Vasoretec</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alicante | Calnate | Cinbenon | Cinbenon teisan | Enalamerck | Enalapril | Enalart | Enalin | Intonis | Lariludon | Lariludon alfresa | Lariludon ohara | Lenaberic | Lenaberic choseido | Lenimec | Lerite | Pharpril | Prylkicin | Renivace | Reniveze | Renopent | Revinbace | Selis | Spaciol | Zacool</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Acepril | Bql | Cardace | Cortec | Dawapril | Ena denk | Enacare | Enalapril agio | Enam | Enapril | Enaril | Encardil | Enril | Envas | Euril | Flaminopril | Invoril | Korandil | Priloten | Vasopril | Zotapril</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A-rin | Alphrin | Antens | Atron | Basopril | Beartec | Beta | Cmg enalapril maleate | Coniten | Daewoo enalapril | Davirong | Debunpril | Dongkwang enalapril | Ecaril | Efnal | Eipril | Elapril | Elfonal | Elip | Ellapril | Elpril | Elprin | Emaleine | Enagrab | Enahexal | Enal | Enalace | Enalagen | Enalapril | Enalapril km | Enalin | Enalpril | Enapil | Enaprin | Enaril | Enatec | Enpril | Epotril | Epr | Epranil | Eprin | Erinal | Erip | Erotec | Espron | Hawon enalapril | Hyperil | Hypril | Lenipril | Lepril | Lotril | Lowtril | Malepril | Meranitec | Nalpril | Napril | Napron | Narapril | Narill | Naritec | Neopril | Nepril | Newpril | Pril | Pritec | Ralatoril | Rapril | Raratoril | Renalapin | Renaton | Renitec | Reomin | Repril | Samnam enalapril | SCD Enalapril | Shinapril | Sinil enalapril maleate | Topuril | Unipril | Upril | Vasotal | Vasotec</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Enam | Renitec</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lotrial | Renitec</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Berlipril | Ednyt | Enahexal | Enalapril | Enalapril vitabalans | Enalapril-mepha | Enam | Enap | Enarenal | Enasuno | Enatec | Enazil | Enypril | Invoril | Renitec</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Docenala | Enalapril eg | Renitec</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Berlipril | Dilvas | Ednyt | Enahexal | Enalapril | Enalapril vitabalans | Enalapril-mepha | Enam | Enap | Enarenal | Envas | Enypril | Invoril | Renitec</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Epril | Prilvas | Renitec</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Enatec</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adytenn | Albec | Apo-pyl | Apocora | Belpril | Bionafil | Danapril | Ek 3 | Ekaril | Enaladil | Enalapril | Enalapril bruluagsa | Enalapril GI | Enalapril raam | Enalapril solara | Enalapril wyeth | Enapriwen | Enoval | Feliberal | Genotens | Glioten | Ileveran | Imotoran | Lipraken | Mexilapril | Nalabest | Norpril | Olavac | Primazen | Pulsol | Ralser | Renitec | Vexotil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Acetec | Corprilor | Danssan | Edynt | Enahexal | Enalapril stada | Enapril | Invoril | Renitec | Zynace</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Enaladex | Envas | Macpril | Priloten</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Enalapril | Enalapril Maleaat Merck | Enalaprilmaleaat | Enalaprilmaleaat a | Enalaprilmaleaat aurobindo | Enalaprilmaleaat CF | Enalaprilmaleaat Katwijk | Enalaprilmaleaat PCH | Enalaprilmaleaat sandoz | Enalaprilmaleaat teva | Renitec</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Enalapril | Enalapril gea | Enalapril sandoz | Linatil | Renitec</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Acetec | Arrow Enalapril | Enahexal | Ethics enalapril | M-enalapril | Renitec</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ardilan | Cardiopril | Enalapril | Enalapril genfar | Enalapril mf | Enalten | Enam | Enapressior | Enapril | Enatensil | Glioten | Grifopril | Hiperson | Invoril | Lotrial | Norpril | Qualipress | Renitec</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acebitor | Azepril | Beartec | Dianapril | Enace | Enalapril | Enbid | Hypace | Hypril | Naprilate | Prilsea | Renaton | Renite xl | Renitec | RiteMED Enalapril | Scheepril | Stadenace | Stalpril | Vasotec</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acelar | Alphrin | Amotac | Angiopril | Cardace | Cardil | Cardiotec | Cortec | Enace | Enlap | Enpril | Espron | Hipril | Kalpiren | Laporide | Redopril | Renitec | Stadelant | Vasopril | Zepres</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Benalapril | Ednyt | Enalapril | Enalapril 1 A Pharma | Enalapril vitabalans | Enap | Enapress | Enarenal | Enatec | Enazil | Epril | Mapryl | Renitec</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Enalapril | Epaned | Vasotec</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Balpril | Cetampril | Denapril | Enalapril | Enalapril generis | Enalapril krka | Enalapril merck | Enapress | Enatec | Maleato de enalapril | Malen | Neotensin | Prilan | Renipril | Renitec | Tensazol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Apridal | Ardilan | Armonium | Bilac pres | Cardaten | Cardietic | Cardietic forte | Cardioland | Cardioprotec | Coronan | Dabonal | Disminupres | Ecaton | Eficaz | Enalap | Enalapril as farm | Enalapril clinipharma | Enalapril genfar | Enalapril klonal | Enalapril la sante | Enalapril medicine | Enalapril mintlab | Enalpan | Enalten | Fabotensil | Glioten | Grifopril | Infraten | Inibex | Lotrial | Miocardyl | Pressitam | Renitec | Tencas | Tensapril | Tensil | Tensioreduct</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Angiotec | Iecatec | Lapril | Narapril | Renitec</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ednyt | Enahexal | Enala | Enalap | Enalapril | Enalapril al | Enalapril Arena | Enalapril Fabiol | Enalapril Laropharm | Enalapril lph | Enalapril medico uno | Enalapril sandoz | Enalapril Slavia | Enalapril Terapia | Enam | Enap | Enapril | Enarenal | Invoril | Renitec | Virfen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apo enalapril | Berlipril | Berlipril 5 | Cotrifarm | Ednyt | Enafarm | Enalacor | Enalapril | Enalapril agio | Enalapril akri | Enalapril forte | Enalapril fpo | Enalapril hexal | Enalapril ns | Enalapril ros | Enalapril-akos | Enam | Enan | Enap | Enap c | Enapril | Enarenal | Enpril | Enril | Envas | Envipril | Invoril | Kalpiren | Lerin | Minipril | Myopril | Renipril | Renitec | Vasolapril | Vasopren | Vero enalapril</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ace Press | Angiotec | Apo enalapril | Esopress | Narapril | Renitec | Riapril | Vasopril</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Enalapril Actavis | Enalapril alpharma | Enalapril astimex | Enalapril Copyfarm | Enalapril ivax | Enalapril krka | Enalapril Merck NM | Enalapril Mylan | Enalapril nm pharma | Enalapril orion | Enalapril sandoz | Enalapril stada | Enalapril teva | Enalapril tika | Enalapril vitabalans | Renitec</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Anapril | Apo enalapril | Corprilor | Ecaril | Enalapril | Enap | Enapril | Enaril | Glioten | Invoril | Korandil | Renitec</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Enalapril vitabalans | Enap | Enazil | Olivin | Vasotec</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Berlipril | Ednyt | Enalapril | Enalapril vitabalans | Enap | Kalpiren | Renitec</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anapril | Enace | Enalapril | Enam | Enapril | Enaril | Envas | Icatec | Invoril | Istopril | Kalpiren | Korandil | Lapril | Myopril | Nalopril | Naritec | Paril | Renaril | Renitec | Unaril</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Angiotec | Enapril | Renitec</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Enalap | Enapril | Konveril | Renitec | Vasolapril</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Enalatec | Enaril | Fonitec | Kintec | Landing | Perisafe | Renitec | Royatec | Sintec | Synbot</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Berlipril | Ednyt | Ena sandoz | Enahexal | Enal | Enalapril | Enalapril darnitsa | Enalapril Zdorovje | Enalozid mono | Enam | Enap | Enapril | Envas | Invoril | Minipril | Miopryl | Renitec</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ena denk | Enapril | Envas</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bi tensil | Cardietic | Ecabloc | Enalapril | Enalapril maleato | Enalapril phs | Enapres | Europril | Fabotensil | Lotrial | Naprilan | Prilen | Renalic | Renitec</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cosil | Dinid | Enalapril | Enalapril alfa | Enalapril maleato | Enam | Enaprival | Enatan | Enecal | Enoval | Fibrosan | Hiperpril | Invoril | Lapril | Prilace | Redopril | Reminal | Renitec | Tesoren</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Aginaril | Bidinatec | Gygaril | Hasitec | Korantrec | Renatab | Usapril</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-enalapril | Alapren | Austell enalapril | Ciplatec | Enalapril | Enalapril arya | Enalapril biotech | Enalapril unicorn | Enap | Envas | Hr-enalapril maleate | Hypace | Pharmapress | Renitec</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Acenopril | Converten | E-pril | Ena denk | Enamate | Enap | Enapril | Encardil | Envas | Epril | Eril | Finapril | Hr-enalapril maleate | Korandil | Luxopril | Nalop | Napril | Priloten | Vasopril</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Enapril | Envas | Korandil | Rennimed</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31226134">
<a name="31226134"></a>Adelborg K, Nicolaisen SK, Hasvold P, Palaka E, Pedersen L, Thomsen RW. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study. <i>PLoS One</i>. 2019;14(6):e0218739. doi:10.1371/journal.pone.0218739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/31226134/pubmed" id="31226134" target="_blank">31226134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9861226">
<a name="9861226"></a>Albareda MM, Corcoy R. Reversible impairment of renal function associated with enalapril in a diabetic patient. <i>CMAJ</i>. 1998;159(10):1279-1281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/9861226/pubmed" id="9861226" target="_blank">9861226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8773167">
<a name="8773167"></a>Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. <i>Ann Pharmacother</i>. 1996;30(1):55-61. doi:10.1177/106002809603000110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8773167/pubmed" id="8773167" target="_blank">8773167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28767167">
<a name="28767167"></a>Alharbi FF, Kholod AAV, Souverein PC, et al. The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase. <i>Fundam Clin Pharmacol</i>. 2017;31(6):676-684. doi:10.1111/fcp.12313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/28767167/pubmed" id="28767167" target="_blank">28767167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479763">
<a name="12479763"></a>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>JAMA. </i>2002;288(23):2981-2997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/12479763/pubmed" id="12479763" target="_blank">12479763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8822986">
<a name="8822986"></a>Annane D, Bellissant E, Pussard E, et al, “Placebo-Controlled, Randomized, Double-Blind Study of Intravenous Enalaprilat Efficacy and Safety in Acute Cardiogenic Pulmonary Edema,” <i>Circulation</i>, 1996, 94(6):1316-24<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8822986/pubmed" id="8822986" target="_blank">8822986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14648339">
<a name="14648339"></a>Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. <i>Pediatr Nephrol</i>. 2004;19(1):45-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/14648339/pubmed" id="14648339" target="_blank">14648339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20130570">
<a name="20130570"></a>Baker-Smith CM, Benjamin DK Jr, Califf RM, Murphy MD, Li JS, Smith PB. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. <i>Clin Pharmacol Ther</i>. 2010;87(6):668-671. doi:10.1038/clpt.2009.231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/20130570/pubmed" id="20130570" target="_blank">20130570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10724055">
<a name="10724055"></a>Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? <i>Arch Intern Med</i>. 2000;160(5):685-693. doi:10.1001/archinte.160.5.685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10724055/pubmed" id="10724055" target="_blank">10724055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28377081">
<a name="28377081"></a>Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):744-749. doi:10.1016/j.jaip.2017.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/28377081/pubmed" id="28377081" target="_blank">28377081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21035591">
<a name="21035591"></a>Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. <i>Am J Med</i>. 2010;123(11):1016-1030. doi:10.1016/j.amjmed.2010.06.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/21035591/pubmed" id="21035591" target="_blank">21035591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6134901">
<a name="6134901"></a>Barnes JN, Davies ES, Gent CB. Rash, eosinophilia, and hyperkalaemia associated with enalapril. <i>Lancet</i>. 1983;2(8340):41-42. doi:10.1016/s0140-6736(83)90020-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/6134901/pubmed" id="6134901" target="_blank">6134901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25058867">
<a name="25058867"></a>Bezalel S, Mahlab-Guri K, Asher I, Werner B, Sthoeger ZM. Angiotensin-converting enzyme inhibitor-induced angioedema. <i>Am J Med</i>. 2015;128(2):120-125. doi:10.1016/j.amjmed.2014.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/25058867/pubmed" id="25058867" target="_blank">25058867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31119681">
<a name="31119681"></a>Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. <i>J Nephrol</i>. 2019;32(4):499-516. doi:10.1007/s40620-019-00617-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/31119681/pubmed" id="31119681" target="_blank">31119681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23721258">
<a name="23721258"></a>Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. <i>BMC Med</i>. 2013;11:141. doi:10.1186/1741-7015-11-141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/23721258/pubmed" id="23721258" target="_blank">23721258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8689816">
<a name="8689816"></a>Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. <i>Clin Pharmacol Ther.</i> 1996;60(1):8-13. doi:10.1016/S0009-9236(96)90161-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8689816/pubmed" id="8689816" target="_blank">8689816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9218671">
<a name="9218671"></a>Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. <i>JAMA</i>. 1997;278(3):232-233. doi:10.1001/jama.278.3.232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/9218671/pubmed" id="9218671" target="_blank">9218671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28994183">
<a name="28994183"></a>Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature. <i>J Clin Hypertens (Greenwich)</i>. 2017;19(12):1377-1382. doi:10.1111/jch.13097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/28994183/pubmed" id="28994183" target="_blank">28994183</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, "Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada," <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12725609">
<a name="12725609"></a>Carnovale A, Esposito P, Bassano P, Russo L, Uomo G. Enalapril-induced acute recurrent pancreatitis. <i>Dig Liver Dis</i>. 2003;35(1):55-57. doi:10.1016/s1590-8658(02)00012-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/12725609/pubmed" id="12725609" target="_blank">12725609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.1">
<a name="Cattran.1"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17299000">
<a name="17299000"></a>Chandar J, Abitbol C, Montané B, Zilleruelo G. Angiotensin blockade as sole treatment for proteinuric kidney disease in children. <i>Nephrol Dial Transplant</i>. 2007;22(5):1332-1337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/17299000/pubmed" id="17299000" target="_blank">17299000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11034011">
<a name="11034011"></a>Chase MP, Fiarman GS, Scholz FJ, et al, “Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,” <i>J Clin Gastroenterol</i>, 2000, 31(3):254-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/11034011/pubmed" id="11034011" target="_blank">11034011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10988282">
<a name="10988282"></a>Conlin P, Moore T, Swartz S, et al, “Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,” <i>Hypertension</i>, 2000, 36(3):461-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10988282/pubmed" id="10988282" target="_blank">10988282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6099737">
<a name="6099737"></a>Davies RO, Gomez HJ, Irvin JD, et al, "An Overview of the Clinical Pharmacology of Enalapril," <i>Br J Clin Pharmacol</i>, 1984, 18(Suppl 2):215-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/6099737/pubmed" id="6099737" target="_blank">6099737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11045392">
<a name="11045392"></a>Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA. Enalapril and prednisone in children with nephrotic-range proteinuria. <i>Pediatr Nephrol</i>. 2000;14(12):1088-1091.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/11045392/pubmed" id="11045392" target="_blank">11045392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16428706">
<a name="16428706"></a>Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. <i>Chest</i>. 2006;129(1 Suppl):169S-173S. doi:10.1378/chest.129.1_suppl.169S<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/16428706/pubmed" id="16428706" target="_blank">16428706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23551721">
<a name="23551721"></a>Doane J, Stults B. Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review. <i>J Clin Hypertens (Greenwich)</i>. 2013;15(4):230-233. doi:10.1111/jch.12063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/23551721/pubmed" id="23551721" target="_blank">23551721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20093343">
<a name="20093343"></a>Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. <i>Clin J Am Soc Nephrol</i>. 2010;5(4):703-708. doi:10.2215/CJN.07371009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/20093343/pubmed" id="20093343" target="_blank">20093343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12698328">
<a name="12698328"></a>Dutta S, Narang A. Enalapril-induced acute renal failure in a newborn infant. <i>Pediatr Nephrol</i>. 2003;18(6):570-572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/12698328/pubmed" id="12698328" target="_blank">12698328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2068826">
<a name="2068826"></a>Elis A, Lishner M, Lang R, Ravid M. Agranulocytosis associated with enalapril. <i>DICP</i>. 1991;25(5):461-462. doi:10.1177/106002809102500502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/2068826/pubmed" id="2068826" target="_blank">2068826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12580985">
<a name="12580985"></a>Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S. Blood pressure response to conventional and low-dose enalapril in chronic renal failure. <i>Br J Clin Pharmacol</i>. 2003;55(2):139-146. doi:10.1046/j.1365-2125.2003.01764.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/12580985/pubmed" id="12580985" target="_blank">12580985</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Enalaprilat [prescribing information]. Lake Forest, IL: Hospira; April 2019.</div>
</li>
<li>
<div class="reference">
                  Epaned (enalapril) solution [prescribing information]. Wilmington, MA: Azurity Pharmaceuticals Inc; March 2020.</div>
</li>
<li>
<div class="reference">
                  Epaned (enalapril) powder for solution kit [prescribing information]. Greenwood Village, CO: Silvergate Pharmaceuticals Inc; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36481180">
<a name="36481180"></a>Fakhouri F, Schwotzer N, Cabiddu G, et al. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. <i>Kidney Int</i>. 2022:S0085-2538(22)01015-8. doi:10.1016/j.kint.2022.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/36481180/pubmed" id="36481180" target="_blank">36481180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070666">
<a name="25070666"></a>Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>. 2014;130(19):1749-1767. doi: 10.1161/CIR.0000000000000095.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/25070666/pubmed" id="25070666" target="_blank">25070666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704213">
<a name="15704213"></a>Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. <i>Pediatr Blood Cancer</i>. 2005;45(7):982-985.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/15704213/pubmed" id="15704213" target="_blank">15704213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085962">
<a name="25085962"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi: 10.1161/CIR.0000000000000105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/25085962/pubmed" id="25085962" target="_blank">25085962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3);e20171904. doi:10.1542/peds.2017-1904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13678872">
<a name="13678872"></a>Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, “Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),” <i>Lancet</i>, 2003, 362(9386):782-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/13678872/pubmed" id="13678872" target="_blank">13678872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10999979">
<a name="10999979"></a>Frances CD, Noguchi H, Massie BM, et al. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. <i>Arch Intern Med</i>. 2000;160(17):2645-2650.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10999979/pubmed" id="10999979" target="_blank">10999979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31445588">
<a name="31445588"></a>Gillion V, Dragean CA, Dahlqvist G, Jadoul M. Intestinal angioedema from angiotensin converting enzyme inhibitor. <i>Kidney Int</i>. 2019;96(3):798. doi:10.1016/j.kint.2019.02.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/31445588/pubmed" id="31445588" target="_blank">31445588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8111505">
<a name="8111505"></a>Gonzalez-Martinez H, Gaspard JJ, Espino DV. Hyponatremia due to enalapril in an elderly patient. A case report. <i>Arch Fam Med</i>. 1993;2(7):791-793. doi:10.1001/archfami.2.7.791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8111505/pubmed" id="8111505" target="_blank">8111505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1580986">
<a name="1580986"></a>Graafland AD, Doorenbos CJ, van Saase JC. Enalapril-induced anemia in two kidney transplant recipients. <i>Transpl Int</i>. 1992;5(1):51-53. doi:10.1007/BF00337190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/1580986/pubmed" id="1580986" target="_blank">1580986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28084903">
<a name="28084903"></a>Hallberg P, Persson M, Axelsson T, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population. <i>Pharmacogenomics</i>. 2017;18(3):201-213. doi:10.2217/pgs-2016-0184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/28084903/pubmed" id="28084903" target="_blank">28084903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23869492">
<a name="23869492"></a>He YM, Feng L, Huo DM, Yang ZH, Liao YH. Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. <i>Nephrology (Carlton)</i>. 2013;18(9):605-614. doi:10.1111/nep.12134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/23869492/pubmed" id="23869492" target="_blank">23869492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29808707">
<a name="29808707"></a>Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. <i>Ann Pharmacother</i>. 2018;52(11):1143-1151. doi:10.1177/1060028018779082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/29808707/pubmed" id="29808707" target="_blank">29808707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1315003">
<a name="1315003"></a>Hennessy A, Swaminathan S, Johnson JR. Enalapril and reversible acute renal failure. <i>Nephrol Dial Transplant</i>. 1992;7(3):267-269. doi:10.1093/oxfordjournals.ndt.a092119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/1315003/pubmed" id="1315003" target="_blank">1315003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” <i>Circulation</i>, 2011, 124(23):2610-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1336423">
<a name="1336423"></a>Hormigo A, Alves M. Peripheral neuropathy in a patient receiving enalapril. <i>BMJ</i>. 1992;305(6865):1332. doi:10.1136/bmj.305.6865.1332-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/1336423/pubmed" id="1336423" target="_blank">1336423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8462229">
<a name="8462229"></a>Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. <i>Clin Pharmacokinet</i>. 1993;24(3):230-254. doi:10.2165/00003088-199324030-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8462229/pubmed" id="8462229" target="_blank">8462229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2544326">
<a name="2544326"></a>Huttunen K, Grönhagen-Riska C, Fyhrquist F. Enalapril treatment of a nursing with slightly impaired renal function. <i>Clin Nephrol</i>. 1989;31(5):278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/2544326/pubmed" id="2544326" target="_blank">2544326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1616218">
<a name="1616218"></a>Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. <i>Ann Intern Med</i>. 1992;117(3):234-242. doi:10.7326/0003-4819-117-3-234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/1616218/pubmed" id="1616218" target="_blank">1616218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10879671">
<a name="10879671"></a>Kammerl MC, Schaefer RM, Schweda F, Schreiber M, Riegger GA, Krämer BK. Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? <i>Clin Nephrol</i>. 2000;53(6):486-488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10879671/pubmed" id="10879671" target="_blank">10879671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2853960">
<a name="2853960"></a>Kelly JG, Doyle GD, Carmody M, Glover DR, Cooper WD. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. <i>Br J Clin Pharmacol</i>. 1988;26(6):781-786. doi:10.1111/j.1365-2125.1988.tb05319.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/2853960/pubmed" id="2853960" target="_blank">2853960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3004546">
<a name="3004546"></a>Kelly JG, Doyle G, Donohue J, et al. Pharmacokinetics of enalapril in normal subjects and patients with renal impairment. <i>Br J Clin Pharmacol</i>. 1986;21(1):63-69. doi:10.1111/j.1365-2125.1986.tb02823.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/3004546/pubmed" id="3004546" target="_blank">3004546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788967">
<a name="24788967"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/24788967/pubmed" id="24788967" target="_blank">24788967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int.</i> 2021b;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int Suppl</i>. 2012;2(5).</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018935">
<a name="25018935"></a>Kidney Disease Improving Global Outcomes (KDIGO). Chapter 10: immunoglobulin A nephropathy. <i>Kidney Int Suppl (2011).</i> 2012;2(2):209-217. doi: 10.1182/blood.2018852400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/25018935/pubmed" id="25018935" target="_blank">25018935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease Improving Global Outcomes (KDIGO) 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl (2013).</i> 2013;3(1):1-150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36272764">
<a name="36272764"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int.</i> 2022;102(suppl 5):S1-S127. doi:10.1016/j.kint.2022.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/36272764/pubmed" id="36272764" target="_blank">36272764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34556256">
<a name="34556256"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. <i>Kidney Int.</i> 2021a;100(suppl 4):S1-S276. doi:10.1016/j.kint.2021.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/34556256/pubmed" id="34556256" target="_blank">34556256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16043683">
<a name="16043683"></a>Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. <i>Arch Intern Med</i>. 2005;165(14):1637-1642. doi:10.1001/archinte.165.14.1637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/16043683/pubmed" id="16043683" target="_blank">16043683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29884969">
<a name="29884969"></a>Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE inhibitor-induced angioedema: a review. <i>Curr Hypertens Rep</i>. 2018;20(7):55. doi:10.1007/s11906-018-0859-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/29884969/pubmed" id="29884969" target="_blank">29884969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10879662">
<a name="10879662"></a>Lama G, Luongo I, Piscitelli A, Salsano ME. Enalapril: antiproteinuric effect in children with nephrotic syndrome. <i>Clin Nephrol</i>. 2000;53(6):432-436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10879662/pubmed" id="10879662" target="_blank">10879662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8110005">
<a name="8110005"></a>Leversha AM, Wilson NJ, Clarkson PM, Calder AL, Ramage MC, Neutze JM. Efficacy and dosage of enalapril in congenital and acquired heart disease. <i>Arch Dis Child</i>. 1994;70(1):35-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8110005/pubmed" id="8110005" target="_blank">8110005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24233240">
<a name="24233240"></a>Lindle KA, Dinh K, Moffett BS, et al. Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. <i>Pediatr Cardiol</i>. 2014;35(3):499-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/24233240/pubmed" id="24233240" target="_blank">24233240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8069010">
<a name="8069010"></a>Llop R, Gómez-Farran F, Figueras A, Capellà D, Laporte JR. Gynecomastia associated with enalapril and diazepam. <i>Ann Pharmacother</i>. 1994;28(5):671-672. doi:10.1177/106002809402800521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8069010/pubmed" id="8069010" target="_blank">8069010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2538615">
<a name="2538615"></a>Lloyd TR, Mahoney LT, Knoedel D, Marvin WJ Jr, Robillard JE, Lauer RM. Orally administered enalapril for infants with congestive heart failure: a dose-finding study. <i>J Pediatr</i>. 1989;114(4 pt 1):650-654.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/2538615/pubmed" id="2538615" target="_blank">2538615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24743543">
<a name="24743543"></a>Luo JQ, He FZ, Luo ZY, et al. Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension. <i>Pharmacogenet Genomics</i>. 2014;24(6):306-313. doi:10.1097/FPC.0000000000000050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/24743543/pubmed" id="24743543" target="_blank">24743543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26607661">
<a name="26607661"></a>Luo JQ, He FZ, Wang ZM, et al. SLCO1B1 Variants and angiotensin converting enzyme inhibitor (enalapril)-induced cough: a pharmacogenetic study. <i>Sci Rep</i>. 2015;5:17253. doi:10.1038/srep17253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/26607661/pubmed" id="26607661" target="_blank">26607661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8261712">
<a name="8261712"></a>MacFadyen RJ, Meredith PA, Elliott HL. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview. <i>Clin Pharmacokinet</i>. 1993;25(4):274-282. doi:10.2165/00003088-199325040-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8261712/pubmed" id="8261712" target="_blank">8261712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8938674">
<a name="8938674"></a>MacGregor MS, Rowe PA, Watson MA, et al. Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors. <i>Nephron</i>. 1996;74(3):517-521.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8938674/pubmed" id="8938674" target="_blank">8938674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14642633">
<a name="14642633"></a>Macías FM, Campos FR, Salguero TP, Soria PT, Carrasco FG, Martín JM. Ductopenic hepatitis related to enalapril. <i>J Hepatol</i>. 2003;39(6):1091-1092. doi:10.1016/j.jhep.2003.08.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/14642633/pubmed" id="14642633" target="_blank">14642633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2019b">
<a name="Mann.2019b"></a>Mann JFE, Bakris GL. Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2019a">
<a name="Mann.2019a"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32766265">
<a name="32766265"></a>Marceau F, Rivard GE, Gauthier JM, et al. Measurement of bradykinin formation and degradation in blood plasma: relevance for acquired angioedema associated with angiotensin converting enzyme inhibition and for hereditary angioedema due to factor XII or plasminogen gene variants. <i>Front Med (Lausanne)</i>. 2020;7:358. doi:10.3389/fmed.2020.00358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/32766265/pubmed" id="32766265" target="_blank">32766265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8995963">
<a name="8995963"></a>Maringhini A, Termini A, Patti R, Ciambra M, Biffarella P, Pagliaro L. Enalapril-associated acute pancreatitis: recurrence after rechallenge. <i>Am J Gastroenterol</i>. 1997;92(1):166-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8995963/pubmed" id="8995963" target="_blank">8995963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32496628">
<a name="32496628"></a>Maroteau C, Siddiqui MK, Veluchamy A, et al; PREDICTION-ADR. Exome sequencing reveals common and rare variants in F5 associated with ACE inhibitor and angiotensin receptor blocker-induced angioedema. <i>Clin Pharmacol Ther.</i> 2020;108(6):1195-1202. doi:10.1002/cpt.1927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/32496628/pubmed" id="32496628" target="_blank">32496628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25176015">
<a name="25176015"></a>McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med</i>. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/25176015/pubmed" id="25176015" target="_blank">25176015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyer.1">
<a name="Meyer.1"></a>Meyer TE. Primary pharmacologic therapy of heart failure with reduced ejection fraction in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413488">
<a name="18413488"></a>Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. <i>Hypertension.</i> 2008;51(6):1624-1630. doi:10.1161/HYPERTENSIONAHA.108.110270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/18413488/pubmed" id="18413488" target="_blank">18413488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16494512">
<a name="16494512"></a>Momma K. ACE inhibitors in pediatric patients with heart failure. <i>Paediatr Drugs.</i> 2006;8(1):55-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/16494512/pubmed" id="16494512" target="_blank">16494512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31835086">
<a name="31835086"></a>Montinaro V, Cicardi M. ACE inhibitor-mediated angioedema. <i>Int Immunopharmacol.</i> 2020;78:106081. doi:10.1016/j.intimp.2019.106081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/31835086/pubmed" id="31835086" target="_blank">31835086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15482412">
<a name="15482412"></a>Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. <i>J Eval Clin Pract</i>. 2004;10(4):499-509. doi:10.1111/j.1365-2753.2003.00484.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/15482412/pubmed" id="15482412" target="_blank">15482412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32397904">
<a name="32397904"></a>Mu G, Xiang Q, Zhang Z, et al. PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case-control genome-wide study. <i>Pharmacogenomics</i>. 2020;21(9):601-614. doi:10.2217/pgs-2019-0167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/32397904/pubmed" id="32397904" target="_blank">32397904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30672376">
<a name="30672376"></a>Mu G, Xiang Q, Zhou S, et al. Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis. <i>Pharmacogenomics</i>. 2019;20(3):189-212. doi:10.2217/pgs-2018-0157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/30672376/pubmed" id="30672376" target="_blank">30672376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25578409">
<a name="25578409"></a>Mutnuri S, Khan A, Variyam EP. Visceral angioedema: an under-recognized complication of angiotensin-converting enzyme inhibitors. <i>Postgrad Med</i>. 2015;127(2):215-217. doi:10.1080/00325481.2015.1001305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/25578409/pubmed" id="25578409" target="_blank">25578409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8062492">
<a name="8062492"></a>Nakamura H, Ishii M, Sugimura T, Chiba K, Kato H, Ishizaki T. The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. <i>Clin Pharmacol Ther</i>. 1994;56(2):160-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8062492/pubmed" id="8062492" target="_blank">8062492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NCIE.1">
<a name="NCIE.1"></a>National Institute for Health and Care Excellence (NICE). NICE guideline hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7778179">
<a name="7778179"></a>Ok E, Akçiçek F, Töz H, et al. Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation. <i>Transplantation</i>. 1995;59(11):1623-1626.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/7778179/pubmed" id="7778179" target="_blank">7778179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32291375">
<a name="32291375"></a>Oktaviono YH, Kusumawardhani N. Hyperkalemia associated with angiotensin converting Enzyme inhibitor or angiotensin receptor blockers in chronic kidney disease. <i>Acta Med Indones</i>. 2020;52(1):74-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/32291375/pubmed" id="32291375" target="_blank">32291375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7848615">
<a name="7848615"></a>Os I, Bratland B, Dahlöf B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. <i>Am J Hypertens</i>. 1994;7(11):1012-1015. doi:10.1093/ajh/7.11.1012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/7848615/pubmed" id="7848615" target="_blank">7848615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8862965">
<a name="8862965"></a>Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. <i>Drug Saf</i>. 1996;15(1):72-78. doi:10.2165/00002018-199615010-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8862965/pubmed" id="8862965" target="_blank">8862965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363666">
<a name="9363666"></a>Ozbek N, Ozen S, Saatçi U. Enalapril-induced anemia in a renal transplant patient. <i>Acta Paediatr Jpn</i>. 1997;39(5):626-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/9363666/pubmed" id="9363666" target="_blank">9363666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10587334">
<a name="10587334"></a>Packer M, Poole-Wilson PA, Armstrong PW, et al, “Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,” <i>Circulation</i>, 1999, 100(23):2312-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10587334/pubmed" id="10587334" target="_blank">10587334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295051">
<a name="15295051"></a>Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. <i>N Engl J Med</i>. 2004;351(6):585-592. doi:10.1056/NEJMra035279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/15295051/pubmed" id="15295051" target="_blank">15295051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12879551">
<a name="12879551"></a>Peppers MP. Myalgia and arthralgia associated with enalapril and ramipril. <i>Am J Health Syst Pharm</i>. 1995;52(2):203-204. doi:10.1093/ajhp/52.2.203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/12879551/pubmed" id="12879551" target="_blank">12879551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7645558">
<a name="7645558"></a>Perazella M, McPhedran P, Kliger A, et al. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. <i>Am J Kidney Dis</i>. 1995;26(3):495-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/7645558/pubmed" id="7645558" target="_blank">7645558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perkovic.1">
<a name="Perkovic.1"></a>Perkovic V. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9193433">
<a name="9193433"></a>Pfeffer MA, Greaves SC, Arnold JM, et al, “Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,” <i>Circulation</i>, 1997, 95(12):2643-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/9193433/pubmed" id="9193433" target="_blank">9193433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14610160">
<a name="14610160"></a>Pfeffer MA, McMurray JJ, Velazquez EJ, et al, “Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,” <i>N Engl J Med</i>, 2003, 349(20):1893-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/14610160/pubmed" id="14610160" target="_blank">14610160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12761258">
<a name="12761258"></a>Praga M, Gutiérrez E, González E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. <i>J Am Soc Nephrol</i>. 2003;14(6):1578-1583. doi: 10.1097/01.asn.0000068460.37369.dc.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/12761258/pubmed" id="12761258" target="_blank">12761258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27490717">
<a name="27490717"></a>Prieto-García L, Pericacho M, Sancho-Martínez SM, et al. Mechanisms of triple whammy acute kidney injury. <i>Pharmacol Ther</i>. 2016;167:132-145. doi:10.1016/j.pharmthera.2016.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/27490717/pubmed" id="27490717" target="_blank">27490717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883995">
<a name="21883995"></a>Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cardiovasc Ther</i>. 2012;30(3):e156-166. doi:10.1111/j.1755-5922.2010.00258.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/21883995/pubmed" id="21883995" target="_blank">21883995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9437375">
<a name="9437375"></a>Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? <i>Arch Intern Med</i>. 1998;158(1):26-32. doi:10.1001/archinte.158.1.26<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/9437375/pubmed" id="9437375" target="_blank">9437375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2158450">
<a name="2158450"></a>Redman CW, Kelly JG, Cooper WD. The excretion of enalapril and enalaprilat in human breast milk. <i>Eur J Clin Pharmacol</i>. 1990;38(1):99. doi:10.1007/BF00314815<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/2158450/pubmed" id="2158450" target="_blank">2158450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reeder.1">
<a name="Reeder.1"></a>Reeder GS, Kennedy HL. Overview of the non-acute management of ST elevation myocardial infarction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2019a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reeder.2">
<a name="Reeder.2"></a>Reeder GS. Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 4, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8165703">
<a name="8165703"></a>Rell K, Koziak K, Jarzyo I, et al. Correction of posttransplant erythrocytosis with enalapril. <i>Transplantation</i>. 1994;57(7):1059-1063.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8165703/pubmed" id="8165703" target="_blank">8165703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22754420">
<a name="22754420"></a>Rosenbaum AJ, Luciano JA, Marburger R, Hume E. Acute kidney injury in the setting of knee arthroplasty: a case report and discussion investigating Angiotensin-converting enzyme inhibitors as the culprit. <i>HSS J</i>. 2011;7(2):183-186. doi:10.1007/s11420-010-9189-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/22754420/pubmed" id="22754420" target="_blank">22754420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1649713">
<a name="1649713"></a>Rush JE, Snyder DL, Barrish A, Hichens M. Comment on Huttunen K, Grönhagen-Riska C, Fyhrquist F, 1989. Enalapril treatment of a nursing mother with slightly impaired renal function. <i>Clin Nephrol.</i> 31:278. <i>Clin Nephrol.</i> 1991;35(5):234.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/1649713/pubmed" id="1649713" target="_blank">1649713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992489">
<a name="25992489"></a>Sato A, Fukuda S. A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. <i>Clin Exp Hypertens</i>. 2015;37(7):563-568. doi:10.3109/10641963.2015.1026040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/25992489/pubmed" id="25992489" target="_blank">25992489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33492725">
<a name="33492725"></a>Sato M, Takahashi M, Kario K. Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary. <i>J Clin Hypertens (Greenwich)</i>. 2021;23(3):692-695. doi:10.1111/jch.14189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/33492725/pubmed" id="33492725" target="_blank">33492725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10645036">
<a name="10645036"></a>Sasinka MA, Podracka L, Boor A, et al, "Enalapril Treatment of Proteinuria in Normotensive Children," <i>Bratisl Lek Listy</i>, 1999, 100(9):476-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10645036/pubmed" id="10645036" target="_blank">10645036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8645963">
<a name="8645963"></a>Schilder JL, Van den Anker JN. Use of enalapril in neonatal hypertension. <i>Acta Paediatr</i>. 1995;84(12):1426-1428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8645963/pubmed" id="8645963" target="_blank">8645963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11602506">
<a name="11602506"></a>Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. <i>Circulation</i>. 2001;104(16):1985-1991. doi:10.1161/hc4101.096153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/11602506/pubmed" id="11602506" target="_blank">11602506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31888533">
<a name="31888533"></a>Scott J, Jones T, Redaniel MT, May MT, Ben-Shlomo Y, Caskey F. Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: A population based cohort study using the clinical practice research datalink. <i>BMC Nephrol</i>. 2019;20(1):481. doi:10.1186/s12882-019-1633-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/31888533/pubmed" id="31888533" target="_blank">31888533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1652404">
<a name="1652404"></a>Sica DA, Cutler RE, Parmer RJ, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. <i>Clin Pharmacokinet</i>. 1991;20(5):420-427. doi:10.2165/00003088-199120050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/1652404/pubmed" id="1652404" target="_blank">1652404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2840522">
<a name="2840522"></a>Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. <i>JAMA</i>. 1988;260(7):967-970.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/2840522/pubmed" id="2840522" target="_blank">2840522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32835726">
<a name="32835726"></a>Smeets NJL, Schreuder MF, Dalinghaus M, et al. Pharmacology of enalapril in children: a review. <i>Drug Discov Today</i>. Published online August 21, 2020. doi:10.1016/j.drudis.2020.08.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/32835726/pubmed" id="32835726" target="_blank">32835726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al, “AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,” <i>Circulation</i>, 2011, 124(22):2458-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9824192">
<a name="9824192"></a>Smoger SH and Sayed MA, “Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,” <i>South Med J</i>, 1998, 91(11):1060-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/9824192/pubmed" id="9824192" target="_blank">9824192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26871774">
<a name="26871774"></a>Sun W, Zhang H, Guo J, et al. Comparison of the efficacy and safety of different ACE inhibitors in patients with chronic heart failure: a PRISMA-compliant network meta-analysis. <i>Medicine (Baltimore)</i>. 2016;95(6):e2554. doi:10.1097/MD.0000000000002554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/26871774/pubmed" id="26871774" target="_blank">26871774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6091806">
<a name="6091806"></a>Till AE, Gomez HJ, Hichens M, et al, "Pharmacokinetics of Repeated Single Oral Doses of Enalapril Maleate (MK-421) in Normal Volunteers," <i>Biopharm Drug Dispos</i>, 1984, 5(3):273-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/6091806/pubmed" id="6091806" target="_blank">6091806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2342045">
<a name="2342045"></a>Todd P, Levison D, Farthing MJ. Enalapril-related cholestatic jaundice. <i>J R Soc Med</i>. 1990;83(4):271-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/2342045/pubmed" id="2342045" target="_blank">2342045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1357311">
<a name="1357311"></a>Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. <i>Lancet</i>. 1992;340(8824):908. doi:10.1016/0140-6736(92)93314-d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/1357311/pubmed" id="1357311" target="_blank">1357311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6289858">
<a name="6289858"></a>Ulm EH, Hichens M, Gomez HJ, et al, "Enalapril Maleate and a Lysine Analogue (MK-521): Disposition in Man," <i>Br J Clin Pharmacol</i>, 1982, 14(3):357-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/6289858/pubmed" id="6289858" target="_blank">6289858</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vasotec (enalapril) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; December 2020.</div>
</li>
<li>
<div class="reference">
                  Vasotec (enalapril) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vlahakos.1">
<a name="Vlahakos.1"></a>Vlahakos DV, Alasfar S. Kidney transplantation in adults: Posttransplant erythrocytosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10644922">
<a name="10644922"></a>von Vigier RO, Mozzettini S, Truttmann AC, Meregalli P, Ramelli GP, Bianchetti MG. Cough is common in children prescribed converting enzyme inhibitors. <i>Nephron</i>. 2000;84(1):98. doi:10.1159/000045552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10644922/pubmed" id="10644922" target="_blank">10644922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10619572">
<a name="10619572"></a>Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? <i>Am J Hypertens</i>. 1999;12(12 Pt 3):195S-203S. doi:10.1016/s0895-7061(99)00104-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10619572/pubmed" id="10619572" target="_blank">10619572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20150448">
<a name="20150448"></a>Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. <i>Clin J Am Soc Nephrol</i>. 2010;5(3):531-548. doi:10.2215/CJN.07821109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/20150448/pubmed" id="20150448" target="_blank">20150448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. <i>Hypertension</i>. 2018;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12920631">
<a name="12920631"></a>White CT, Macpherson CF, Hurley RM, Matsell DG. Antiproteinuric effects of enalapril and losartan: a pilot study. <i>Pediatr Nephrol</i>. 2003;18(10):1038-1043.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/12920631/pubmed" id="12920631" target="_blank">12920631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20625347">
<a name="20625347"></a>Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. <i>Pharmacogenet Genomics.</i> 2010;20(9):532-536. doi:10.1097/FPC.0b013e32833d3acb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/20625347/pubmed" id="20625347" target="_blank">20625347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8703645">
<a name="8703645"></a>Yeo WW, Chadwick IG, Kraskiewicz M, Jackson PR, Ramsay LE. Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. <i>Br J Clin Pharmacol</i>. 1995;40(5):423-429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/8703645/pubmed" id="8703645" target="_blank">8703645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11502994">
<a name="11502994"></a>Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. <i>Transplantation</i>. 2001;72(3):542-544.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/11502994/pubmed" id="11502994" target="_blank">11502994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10639539">
<a name="10639539"></a>Yusuf S, Sleight P, Pogue J, et al, “Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,” <i>N Engl J Med</i>, 2000, 342(3):145-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enalapril-drug-information/abstract-text/10639539/pubmed" id="10639539" target="_blank">10639539</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9405 Version 625.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
